Placeholder Banner

Industry Outlook in Anticipation of the 2012 BIO International Convention

February 28, 2012
This month, BIO wrapped the 14th Annual CEO & Investor Conference in New York City at the Waldorf=Astoria. Hosted by BIO, the event drew more than 1,200 industry leaders, featured 140 company presentations and a record breaking 1,300+ one-on-one meetings between 225 companies.

Taking the momentum from this meeting, we now look ahead to the 2012 BIO International Convention to be held June 18 – 21, 2012 at the Boston Convention & Exhibition Center in Boston, MA. One hot topic that seemed to dominate panel conversations, many of which drew participation from company CEO’s like Pfizer and Gilead, was the increase in Food and Drug Administration (FDA) approvals.  In 2012 alone, four new drugs have been approved by the FDA: Bydureon for type 2 diabetes; Kalydeco for cystic fibrosis; Erivedge for basal cell carcinoma and Inlyta for renal cell carcinoma, with two more approved with companion diagnostics: Xalkori for NSCLC and Zelboraf for metastatic melanoma.

The therapeutic areas that generated the biggest buzz included oncology, hepatitis C and Alzheimer’s. Those looking to learn more about the breakthroughs and advancements in these areas should visit the Convention site to explore the more than 125 thought-provoking Breakout Sessions in the thirteen relevant tracks.

Additionally, investor optimism appears restored according to the recently released BIO Industry Analysis Survey. The survey results showed that the majority of investors believe this is a good time to invest in biotech and expect that there will be more IPOs this year compared to last year.

Looking ahead to the Convention, we anticipate these trends and investor optimism will continue to play out in Boston. Through the opportunities presented at the BIO Business Forum, from partnering meetings to hosting a company presentation, to the various networking events, now is the time for organizations to capitalize on the global reach opportunities available at the Convention.

Don’t miss out on the chance to be a part of the global event for biotechnology. To learn more about the Convention and what business development opportunities await, please visit here.